MCID: ACT098
MIFTS: 52

Acute Erythroid Leukemia

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Acute Erythroid Leukemia

MalaCards integrated aliases for Acute Erythroid Leukemia:

Name: Acute Erythroid Leukemia 38 53
Acute Myeloid Leukemia, M6 Type 29 6
Acute Myeloid Leukemia Fab-M6 53 73
Acute Erythroleukemia 53 73
Erythroleukemia 53 55
Acute Erythroleukemia - M6a Subtype 73
Acute Erythroleukemia - M6b Subtype 73
Acute Erythroleukemia M6a Subtype 53
Acute Erythroleukemia M6b Subtype 53
Acute Erythroblastic Leukemia 73
Acute Myeloid Leukemia M6 53
Di Guglielmo's Syndrome 53
Di Guglielmo Syndrome 53
Aml M6 53
Aml-M6 53

Classifications:



Summaries for Acute Erythroid Leukemia

MalaCards based summary : Acute Erythroid Leukemia, also known as acute myeloid leukemia, m6 type, is related to refractory anemia and myelofibrosis. An important gene associated with Acute Erythroid Leukemia is PTGIR (Prostaglandin I2 Receptor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and hematopoietic system

Wikipedia : 76 Acute erythroid leukemia or Di Guglielmo syndrome is a rare form of acute myeloid leukemia (less than 5%... more...

Related Diseases for Acute Erythroid Leukemia

Diseases related to Acute Erythroid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 refractory anemia 29.3 EPO JAK2
2 myelofibrosis 28.7 EPO GATA1 JAK2
3 myelodysplastic syndrome 28.7 EPO EPOR GATA1 JAK2
4 erythroleukemia, familial 11.2
5 anemia, congenital dyserythropoietic, type iii 11.1
6 fetal hemoglobin quantitative trait locus 1 10.5 HBB HBG1
7 leukemia 10.5
8 neutrophil-specific granule deficiency 10.4 GATA1 SPI1
9 spherocytosis, type 4 10.4 GATA1 KLF1
10 spherocytosis, type 3 10.4 GATA1 KLF1
11 hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome 10.3 HBB HBG1 KLF1
12 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 10.3 HBB HBG1 KLF1
13 spherocytosis, type 2 10.2 GATA1 HBB KLF1
14 pernicious anemia 10.0
15 retinitis pigmentosa and erythrocytic microcytosis 10.0 EPO JAK2
16 megakaryocytic leukemia 9.9
17 macrocytic anemia 9.9
18 thrombocytopenia-absent radius syndrome 9.9 GATA1 JAK2
19 hereditary spherocytosis 9.9 GATA1 HBB HBG1 KLF1
20 splenomegaly 9.8 EPO JAK2
21 erythrocytosis, familial, 2 9.8 EPO EPOR
22 splenic disease 9.8 EPO HBB
23 leukemia, chronic lymphocytic 2 9.8
24 leukemia, chronic lymphocytic 9.8
25 myeloma, multiple 9.8
26 acute leukemia 9.8
27 vasculitis 9.8
28 leukemia, b-cell, chronic 9.8
29 pyridoxine-refractory autosomal recessive sideroblastic anemia 9.8
30 congenital dyserythropoietic anemia 9.8
31 acquired idiopathic sideroblastic anemia 9.8
32 acquired polycythemia 9.7 EPO EPOR JAK2
33 primary polycythemia 9.7 EPO EPOR JAK2
34 immune system disease 9.7 EPO HBB JAK2
35 sickle cell disease 9.7 EPO HBB HBG1
36 sickle cell anemia 9.7 EPO HBB HBG1
37 erythrocytosis, familial, 1 9.7 EPO EPOR JAK2
38 polycythemia 9.6 EPO EPOR JAK2
39 alpha-thalassemia 9.6 EPO HBB HBG1
40 polycythemia vera 9.6 EPO EPOR JAK2
41 neonatal anemia 9.6 EPO EPOR KLF1
42 anemia of prematurity 9.4 EPO EPOR
43 ewing's family of tumors 9.4 EPO EPOR FLI1
44 thalassemia 9.4 EPO GATA1 HBB HBG1
45 hemoglobinopathy 9.3 EPO HBB HBG1 KLF1
46 congenital hemolytic anemia 9.3 EPO HBB HBG1 KLF1
47 bone marrow cancer 9.3 EPO EPOR GATA1 JAK2
48 essential thrombocythemia 9.3 EPO EPOR GATA1 JAK2
49 leukemia, chronic myeloid 9.3 EPO GATA1 JAK2
50 deficiency anemia 9.3 EPO EPOR GATA1 HBB

Graphical network of the top 20 diseases related to Acute Erythroid Leukemia:



Diseases related to Acute Erythroid Leukemia

Symptoms & Phenotypes for Acute Erythroid Leukemia

MGI Mouse Phenotypes related to Acute Erythroid Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 EPO EPOR FLI1 GATA1 HSF2 JAK2
2 hematopoietic system MP:0005397 10.02 EPOR FLI1 GATA1 JAK2 KLF1 PTGIR
3 cardiovascular system MP:0005385 10 TAL1 EPO EPOR FLI1 GATA1 HSF2
4 homeostasis/metabolism MP:0005376 9.97 EPO EPOR GATA1 HSF2 JAK2 KLF1
5 embryo MP:0005380 9.95 EPO EPOR FLI1 GATA1 JAK2 KLF1
6 immune system MP:0005387 9.91 EPO EPOR FLI1 GATA1 JAK2 KLF1
7 integument MP:0010771 9.63 EPO GATA1 JAK2 KLF1 PTGIR TAL1
8 liver/biliary system MP:0005370 9.5 EPO EPOR FLI1 GATA1 JAK2 KLF1
9 mortality/aging MP:0010768 9.32 JAK2 KLF1 PTGIR SPI1 TAL1 EPO

Drugs & Therapeutics for Acute Erythroid Leukemia

Drugs for Acute Erythroid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
4
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
5
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
8
Mesna Approved, Investigational Phase 3 3375-50-6 598
9
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
10
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
11
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
12
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
13
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
14
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
16
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
17
Prednisone Approved, Vet_approved Phase 3,Phase 1 53-03-2 5865
18
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
19
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Carmustine Approved, Investigational Phase 3 154-93-8 2578
22
Hydroxyurea Approved Phase 3 127-07-1 3657
23
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
24
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
25
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
26
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
27
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
28
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
29
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
30
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
31
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
32
Cyproheptadine Approved Phase 3 129-03-3 2913
33
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
37
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
38
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
39 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
40 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Analgesics Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
48 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
2 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
3 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
4 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Completed NCT00136084 Phase 3 Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
9 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
10 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
13 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
14 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
15 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
16 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
17 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
18 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
19 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
20 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
22 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
23 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
24 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
25 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
26 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
27 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
28 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
29 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
30 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
31 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
34 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
37 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
38 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
39 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
40 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
41 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
42 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
43 Vorinostat in Treating Patients With Acute Myeloid Leukemia Completed NCT00305773 Phase 2 vorinostat;vorinostat
44 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
45 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
46 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
47 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
48 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib

Search NIH Clinical Center for Acute Erythroid Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Erythroid Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Erythroid Leukemia

Genetic tests related to Acute Erythroid Leukemia:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia, M6 Type 29

Anatomical Context for Acute Erythroid Leukemia

MalaCards organs/tissues related to Acute Erythroid Leukemia:

41
Myeloid, Bone, Bone Marrow, Breast

Publications for Acute Erythroid Leukemia

Articles related to Acute Erythroid Leukemia:

(show all 33)
# Title Authors Year
1
An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification. ( 28793875 )
2017
2
Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. ( 28886412 )
2017
3
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. ( 27443511 )
2016
4
The disappearance of acute erythroid leukemia: An act of legerdemain at the World Health Organization. ( 27667167 )
2016
5
microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. ( 27086927 )
2016
6
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. ( 27244257 )
2016
7
Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia. ( 27389056 )
2016
8
Extreme dyserythropoiesis in the setting of acute erythroid leukemia. ( 26605391 )
2015
9
Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. ( 26202927 )
2015
10
Differential diagnoses of macrocytic anemia, reticulocytosis and low serum haptoglobin in patients with myelodysplastic syndromes/acute leukemia: comment on "two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis". ( 24390535 )
2014
11
Acute erythroid leukemia in a patient with chronic lymphocytic leukemia. ( 25536628 )
2014
12
Large vessel vasculitis developed early after allogeneic bone marrow transplant for acute erythroid leukemia. ( 23517561 )
2013
13
Two cases of acute erythroid leukemia presenting with marked macrocytic anemia, reticulocytosis and hemolysis. ( 23812200 )
2013
14
Fusion of ZMYND8 and RELA genes in acute erythroid leukemia. ( 23667654 )
2013
15
Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy. ( 23871646 )
2013
16
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. ( 23648669 )
2013
17
High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). ( 23032695 )
2013
18
Erythropoietin-induced acute erythroid leukemia-like picture: A potential pitfall. ( 24239851 )
2013
19
Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification. ( 21780998 )
2012
20
Block of red blood cell maturation in acute erythroid leukemia. ( 23115799 )
2012
21
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. ( 21996560 )
2012
22
S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13). ( 22147971 )
2011
23
FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia. ( 22829078 )
2011
24
Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. ( 21264917 )
2011
25
Acute erythroid leukemia with multilineage dysplasia in a cat. ( 21731091 )
2011
26
Translocation t(1;16)(p31;q24) rearranging CBFA2T3 is specific for acute erythroid leukemia. ( 21606959 )
2011
27
Acute erythroid leukemia. ( 20807044 )
2010
28
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. ( 20040759 )
2010
29
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. ( 20473273 )
2010
30
Recommendation of the use of myeloblast percentage among non-erythroid cells instead of percentage among total nucleated cells for therapeutic response assessment in acute erythroid leukemia. ( 16690527 )
2006
31
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. ( 16034466 )
2005
32
Acute erythroid leukemia (M6): outcome of bone marrow transplantation. ( 10512167 )
1999
33
Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases. ( 1068531 )
1976

Variations for Acute Erythroid Leukemia

ClinVar genetic disease variations for Acute Erythroid Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ERBB3 NM_001982.3(ERBB3): c.4009G> A (p.Ala1337Thr) single nucleotide variant Likely pathogenic rs755855285 GRCh38 Chromosome 12, 56102035: 56102035
2 ERBB3 NM_001982.3(ERBB3): c.4009G> A (p.Ala1337Thr) single nucleotide variant Likely pathogenic rs755855285 GRCh37 Chromosome 12, 56495819: 56495819

Expression for Acute Erythroid Leukemia

Search GEO for disease gene expression data for Acute Erythroid Leukemia.

Pathways for Acute Erythroid Leukemia

GO Terms for Acute Erythroid Leukemia

Cellular components related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.13 KLF1 SPI1 TAL1
2 hemoglobin complex GO:0005833 8.62 HBB HBG1

Biological processes related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 FLI1 GATA1 HSF2 SPI1 TAL1
2 regulation of transcription by RNA polymerase II GO:0006357 9.93 EPO FLI1 HSF2 KLF1 SPI1 TAL1
3 response to lipopolysaccharide GO:0032496 9.74 EPO JAK2 PTGIR
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.71 JAK2 NPTN PTGIR
5 blood coagulation GO:0007596 9.62 GATA1 HBB HBG1 JAK2
6 platelet aggregation GO:0070527 9.6 GATA1 HBB
7 blood circulation GO:0008015 9.59 EPO FLI1
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 HBB JAK2
9 regulation of hematopoietic stem cell differentiation GO:1902036 9.58 GATA1 SPI1 TAL1
10 positive regulation of erythrocyte differentiation GO:0045648 9.56 GATA1 TAL1
11 myeloid cell differentiation GO:0030099 9.55 GATA1 TAL1
12 platelet formation GO:0030220 9.52 GATA1 TAL1
13 oxygen transport GO:0015671 9.51 HBB HBG1
14 embryonic hemopoiesis GO:0035162 9.49 GATA1 TAL1
15 megakaryocyte development GO:0035855 9.48 FLI1 TAL1
16 erythrocyte maturation GO:0043249 9.43 EPO TAL1
17 positive regulation of transcription, DNA-templated GO:0045893 9.43 EPO FLI1 GATA1 KLF1 SPI1 TAL1
18 megakaryocyte differentiation GO:0030219 9.37 GATA1 TAL1
19 erythropoietin-mediated signaling pathway GO:0038162 9.26 EPO EPOR
20 basophil differentiation GO:0030221 9.16 GATA1 TAL1
21 erythrocyte differentiation GO:0030218 9.1 EPO GATA1 JAK2 KLF1 SPI1 TAL1

Molecular functions related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.88 FLI1 GATA1 HSF2 KLF1 SPI1 TAL1
2 DNA binding transcription factor activity GO:0003700 9.73 FLI1 GATA1 HSF2 KLF1 SPI1 TAL1
3 heme binding GO:0020037 9.54 HBB HBG1 JAK2
4 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.33 FLI1 SPI1 TAL1
5 oxygen carrier activity GO:0005344 9.32 HBB HBG1
6 RNA polymerase II transcription factor binding GO:0001085 9.13 GATA1 SPI1 TAL1
7 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.02 FLI1 GATA1 HSF2 SPI1 TAL1

Sources for Acute Erythroid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....